Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN.
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
14
03
2023
accepted:
17
08
2023
pmc-release:
01
11
2024
medline:
9
11
2023
pubmed:
24
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
C3 glomerulopathy and idiopathic immunoglobulin-mediated membranoproliferative GN (Ig-MPGN) are rare complement-mediated kidney diseases. Inherited forms of C3 glomerulopathy/Ig-MPGN are rarely described. Three hundred ninety-eight patients with C3 glomerulopathy ( n =296) or Ig-MPGN ( n =102) from a national registry were screened for three complement genes: factor H ( CFH ), factor I ( CFI ), and C3 . Patients with rare variant (minor allele frequency <0.1%) were included. Epidemiologic, clinical, and immunologic data at diagnosis and kidney outcomes of patients were retrospectively collected. Fifty-three different rare variants, including 30 (57%), 13 (24%), and ten (19%) in CFH , CFI , and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified as pathogenic, including 20/30 (66%) and 11/13 (84%) variants in CFH and CFI , respectively, impairing synthesis of factor H or factor I regulators. Fifteen of 53 (27%) variants were of unknown significance. At diagnosis, 69% of patients were adult (median age of 31 years). With the exception of biologic stigma of thrombotic microangiopathy, which was more frequent in patients with CFI variants (5/14 [36%] versus 1/37 [3%] and 0% in the CFH group and C3 group, respectively, P < 0.001), the clinical and histologic features were similar among the three variants groups. The kidney outcome was poor regardless of the age at onset and treatment received. Sixty-five percent (43/66) of patients with rare variant reach kidney failure after a median delay of 41 (19-104) months, compared with 28% (55/195) after a median delay of 34 (12-143) months in the nonvariant group. Among 36 patients who received a kidney transplant, 2-year recurrence was frequent, occurring in 39% (12/31), without difference between variant groups, and led to graft failure in three cases. In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH , CFI , or C3 genes. In most cases, a quantitative deficiency in factor H or factor I was identified. The presence of a rare variant was associated with poor kidney survival. This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_08_CJN0000000000000252.mp3.
Sections du résumé
BACKGROUND
C3 glomerulopathy and idiopathic immunoglobulin-mediated membranoproliferative GN (Ig-MPGN) are rare complement-mediated kidney diseases. Inherited forms of C3 glomerulopathy/Ig-MPGN are rarely described.
METHODS
Three hundred ninety-eight patients with C3 glomerulopathy ( n =296) or Ig-MPGN ( n =102) from a national registry were screened for three complement genes: factor H ( CFH ), factor I ( CFI ), and C3 . Patients with rare variant (minor allele frequency <0.1%) were included. Epidemiologic, clinical, and immunologic data at diagnosis and kidney outcomes of patients were retrospectively collected.
RESULTS
Fifty-three different rare variants, including 30 (57%), 13 (24%), and ten (19%) in CFH , CFI , and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified as pathogenic, including 20/30 (66%) and 11/13 (84%) variants in CFH and CFI , respectively, impairing synthesis of factor H or factor I regulators. Fifteen of 53 (27%) variants were of unknown significance. At diagnosis, 69% of patients were adult (median age of 31 years). With the exception of biologic stigma of thrombotic microangiopathy, which was more frequent in patients with CFI variants (5/14 [36%] versus 1/37 [3%] and 0% in the CFH group and C3 group, respectively, P < 0.001), the clinical and histologic features were similar among the three variants groups. The kidney outcome was poor regardless of the age at onset and treatment received. Sixty-five percent (43/66) of patients with rare variant reach kidney failure after a median delay of 41 (19-104) months, compared with 28% (55/195) after a median delay of 34 (12-143) months in the nonvariant group. Among 36 patients who received a kidney transplant, 2-year recurrence was frequent, occurring in 39% (12/31), without difference between variant groups, and led to graft failure in three cases.
CONCLUSIONS
In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH , CFI , or C3 genes. In most cases, a quantitative deficiency in factor H or factor I was identified. The presence of a rare variant was associated with poor kidney survival.
PODCAST
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_08_CJN0000000000000252.mp3.
Identifiants
pubmed: 37615951
doi: 10.2215/CJN.0000000000000252
pii: 01277230-202311000-00010
pmc: PMC10637453
doi:
Substances chimiques
Complement C3
0
Complement Factor H
80295-65-4
Immunoglobulins
0
Fibrinogen
9001-32-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1435-1445Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
J Am Soc Nephrol. 2016 Jun;27(6):1665-77
pubmed: 26471127
Front Immunol. 2021 Jan 14;11:602284
pubmed: 33519811
Nat Genet. 2016 Feb;48(2):134-43
pubmed: 26691988
Hum Mol Genet. 2020 Aug 11;29(14):2313-2324
pubmed: 32510551
Mol Immunol. 2008 Jan;45(1):95-105
pubmed: 17597211
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Kidney Int. 2018 Apr;93(4):977-985
pubmed: 29310824
Kidney Int. 2012 Aug;82(4):454-64
pubmed: 22456601
J Am Soc Nephrol. 2019 Dec;30(12):2449-2463
pubmed: 31575699
Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62
pubmed: 23307876
Kidney Int. 2022 Oct;102(4):904-916
pubmed: 35752323
Clin J Am Soc Nephrol. 2022 Jul;17(7):994-1007
pubmed: 35777834
Mol Immunol. 2016 Mar;71:131-142
pubmed: 26895476
Blood. 2021 May 6;137(18):2438-2449
pubmed: 33270832
Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1287-1298
pubmed: 32816888
J Am Soc Nephrol. 2004 Mar;15(3):787-95
pubmed: 14978182
Nat Rev Nephrol. 2021 Aug;17(8):543-553
pubmed: 33953366
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):18
pubmed: 32516404
Hum Pathol. 2014 Nov;45(11):2326-33
pubmed: 25260719
Kidney Int. 2013 Dec;84(6):1079-89
pubmed: 24172683
Blood. 2015 Apr 9;125(15):2359-69
pubmed: 25608561
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
J Am Soc Nephrol. 2016 Apr;27(4):1245-53
pubmed: 26283675
J Biol Chem. 1997 Oct 3;272(40):25168-75
pubmed: 9312129
Mayo Clin Proc. 2018 Aug;93(8):991-1008
pubmed: 30077216
Lancet. 2010 Sep 4;376(9743):794-801
pubmed: 20800271
Blood. 2021 Dec 2;138(22):2185-2201
pubmed: 34189567
Kidney Int. 2017 Nov;92(5):1232-1241
pubmed: 28712854
Am J Transplant. 2013 Mar;13(3):663-75
pubmed: 23356914
J Immunol. 2018 Apr 1;200(7):2464-2478
pubmed: 29500241
J Am Soc Nephrol. 2020 Feb;31(2):365-373
pubmed: 31919107
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6873-8
pubmed: 26501415